The Prostate Cancer Foundation (PCF) and Pfizer, Inc. are proud to announce the PCF-Pfizer Global Challenge Awards, a competitive, peer-reviewed Investigator Sponsored Research (ISR) grants program. Approximately $2 million USD is allocated to this research grants program focused on investigating talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in prostate cancer. Through this funding mechanism, PCF and Pfizer will support approximately three (3) innovative clinical investigations or clinical trial correlative research studies surrounding the use of talazoparib in prostate cancer. Applications will be peer-reviewed by an independent review panel led by PCF, composed of expert academic researchers in order to select the most impactful studies for funding. The amount of each award will be determined based on the external review panel’s evaluation of each project.
Area of Research Focus: The intent of this RFP is to invite investigators from around the world to submit innovative proposals for clinical investigations with correlative research for talazoparib in prostate cancer.Research proposals in the following topic areas are preferred:
- _Talazoparib in early and advanced stages of prostate cancer
- _Talazoparib in molecularly-unselected patient populations, as appropriate
- _Combination of talazoparib with novel agents
- _Talazoparib in combination with next-generation androgen axis-targeted therapies (other than enzalutamide)
- _Talazoparib in combination with PSMA radiotherapeutics
- _Identifying resistance mechanisms to talazoparib with treatment strategies to avoid or overcome resistance
For more information please visit: https://researchfunding.duke.edu/pcf-pfizer-global-challenge-awards